• Ann Marie Looney : Analyst, Oncology
• 24 Jun, 2019

Checkpoint inhibitor combination strategies remains a focus of development, but chemo combos are not a slam dunk for every indication. As the 40,000 attendees of this year’s ASCO conference relinquish their hold of the windy city, oncology experts worldwide begin contemplating the wealth of new or expanded data which was presented, and how it might affect their everyday practice.
Read more...